ZILBRYSQ

Growth

zilucoplan

UCB Pharma
NDASUBCUTANEOUSSOLUTION
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
14

Mechanism of Action

Complement Inhibitors

Pharmacologic Class:

Complement Inhibitor

Clinical Trials (5)

NCT07215949Phase 3Recruiting

Zilucoplan for Severe gMG Exacerbations

Started Jan 2026
15 enrolled
Generalized Myasthenia Gravis (gMG)
NCT06961747Phase 1Recruiting

A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

Started Jul 2025
15 enrolled
Healthy Participants
NCT06435312Phase 3Enrolling By Invitation

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Started Nov 2024
8 enrolled
Generalized Myasthenia Gravis
NCT06055959Phase 2/3Recruiting

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Started Oct 2024
8 enrolled
Generalized Myasthenia Gravis
NCT06471361Phase 3Completed

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

Started Aug 2024
31 enrolled
Generalized Myasthenia Gravis

Loss of Exclusivity

LOE Date
Jun 12, 2035
112 months away
Patent Expiry
Jun 12, 2035
Exclusivity Expiry
Oct 17, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
10106579
Jun 12, 2035
SubstanceProduct
U-3735
10208089
Jun 12, 2035
Substance
U-3735
10435438
Jun 12, 2035
Substance
U-3735
10562934
Jun 12, 2035
Substance
—
10835574
Jun 12, 2035
Product
—
Company
UP
UCB Pharma
Belgium - Brussels
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers